Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab

AAPS Journal

Volumn 19, Issue 2, 2017, Pages 468-474

  Bian, Sumin ^a   Ferrante, Marc ^b   Gils, Ann ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

adalimumab; anti drug antibody; drug interference; drug resistant assay; immunogenicity

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; DRUG ANTIBODY; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; INFLIXIMAB;

ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG RESISTANT ANTI ADALIMUMAB ANTIBODY ASSAY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; OUTCOME ASSESSMENT; PROCESS DEVELOPMENT; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; PROCEDURES; VALIDATION STUDY;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLIXIMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84996549789     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-016-0018-8     Document Type: Article

References (21)

1. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van Der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28(9):1122–6. doi:10.1111/j.1365-2036.2008.03828.x.
2. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. Landes Biosci. 2010;2(3):256–65.
3. van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem. 2014;289(50):34482–8. doi:10.1074/jbc.M114.615500.
4. van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EEL, Kruithof S, de Groot E, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2012;104–9. doi: 10.1136/annrheumdis-2012-201445.
5. van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis. 2013;72:1680–6. doi:10.1136/annrheumdis-2012-202407.
6. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 2006;24(6):274–80. doi:10.1016/j.tibtech.2006.04.001.
7. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11(4):243–55. doi:10.1038/nrgastro.2013.253.
8. Bendtzen K. Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol. 2015;6(4):1–5. doi:10.3389/fimmu.2015.00109.
9. Gils A, Vande Casteele N, Poppe R, Van de Wouwer M, Compernolle G, Peeters M, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. 2014;0(0):1–5. doi: 10.1097/FTD.0000000000000074.
10. van Schouwenburg PA, Kruithof S, Wolbink G, Wouters D, Rispens T. Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies. J Pharm Biomed Anal. 2016;120:198–201. doi:10.1016/j.jpba.2015.12.040.
11. van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, et al. An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(9):2172–7. doi:10.1097/MIB.0000000000000434.
12. van Stappen T, Brouwers E, Vermeire S, Gils A. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay. Drug Test Anal. 2016. doi:10.1002/dta.1968.
13. Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007;327(1–2):10–7. doi:10.1016/j.jim.2007.07.004.
14. Zoghbi J, Xu Y, Grabert R, Theobald V, Richards S. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J Immunol Methods. 2015;426:62–9. doi:10.1016/j.jim.2015.08.002.
15. Grabert R, Richards S, Theobald V, Xu YX, Zoghbi J. Assays for detecting the presence or amount of an anti-drug antibody. WO 2015123315 A1. 2015, https://www.google.com/patents/WO2015123315A1?cl=en. Accessed 4 November 2016.
16. Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut. 2012;61:321. doi:10.1136/gut.2010.236869.
17. Bian S, Stappen TV, Baert F, Compernolle G, Brouwers E, Tops S, et al. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. J Pharm Biomed Anal. 2016;125:62–7. doi:10.1016/j.jpba.2016.03.029.
18. Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Salbato J, Reddy R, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal. 2013;78–79:39–44. doi:10.1016/j.jpba.2013.01.031.
19. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–8. doi:10.1016/j.jim.2010.09.005.
20. Kelley M, Ahene AB, Gorovits B, Kamerud J, King LE, McIntosh T, et al. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J. 2013;15(3):646–58. doi:10.1208/s12248-013-9468-4.
21. Dai S, Schantz A, Clements-Egan A, Cannon M, Shankar G. Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity. AAPS J. 2014;16(3):464–77. doi:10.1208/s12248-014-9581-z.